Please login to the form below

Not currently logged in

Sanofi-aventis to acquire US BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences

Sanofi-aventis has announced it has agreed to purchase US biopharmaceutical company, BiPar Sciences.

California-based BiPar specialises in the development of pioneering treatments for several different cancers through DNA repair using PARP (Poly ADP-Ribose Polymerase) inhibitors. BSI-201 enhances the effects of chemotherapy by preventing cancer cells from repairing their own DNA and therefore leading to the death of cancer cells.

BiPar's lead product candidate, BSI-201, is currently undergoing Phase 2 trials for the treatment of metastatic triple negative breast cancer and ovarian cancer among others.

Christopher A Viehbacher, CEO of sanofi-aventis said: "This acquisition illustrates our strong commitment to oncology to provide patients, physicians and public health stakeholders with breakthrough medicines addressing unmet medical needs".

Under the terms of the agreement, the final price of the deal depends on BSI-201 achieving milestone payments. The price could reach a maximum of $500m.

15th April 2009


Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...